Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Remedies

PolyMedix Receives Regulatory Clearance To Initiate Second Phase I Clinical Study Of Novel Systemic Antibiotic Compound
PolyMedix, Inc., an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders, has received a notice of no objection from Health Canada for the Company"s Clinical Trial Application ("CTA") for its defensin mimetic antibiotic compound, PMX-30063. This notice of no objection allows for the initiation of the second human clinical study in Canada. PMX-30063 is a defensin mimetic antibiotic compound, the first of an entirely new class of antibiotic drugs that is believed to work in such a way that makes bacterial resistance unlikely to develop.
generic viagra online
Age Concern And Help The Aged On New Research On Dementia, UK
Commenting on the new research on Alzheimer"s by the the Institute of Psychiatry at King"s College London, Michelle Mitchell, Charity Director for Age Concern and Help the Aged said:
News of the day
Employee Involvement Programs Key To Workplace Diversity
A new study by a University of Arizona professor shows employee involvement programs that executives adopt to increase efficiency also end up improving their record on diversity.
Health Insurance

Amarillo Biosciences Reaches Enrollment Goal In Australian Influenza Phase 2 Clinical Trial

Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) announced that it has reached full enrollment in a Phase 2 clinical study of the company"s oral interferon product at the University of Western Australia located in Perth. A total of 200 healthy volunteers meeting all eligibility criteria have been enrolled to 16 weeks of treatment with oral interferon or matching placebo. The double-blind clinical trial being conducted by Dr. Manfred Beilharz and colleagues is expected to show that lozenges containing a low dose of interferon-alpha can prevent infection or reduce the severity of infection with influenza and other common respiratory viruses when taken once a day during a typical winter cold/flu season. Final study results are expected to be available before the end of the year. Amarillo Biosciences


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009